Kyverna Therapeutics is progressing toward filing its Biologics License Application (BLA) by Q4 2026 for a cell therapy targeting Stiff Person syndrome, a rare autoimmune disease with no current approved treatments. If successful, this would mark the first approved cell therapy for autoimmune diseases globally, positioning Kyverna as a pioneer in this field. The company highlighted its leadership in developing cell therapies for autoimmune conditions during the Morgan Stanley Global Healthcare Conference.
The GraniteShares 2x Long AMD Daily ETF (AMDL) provides 200% leveraged exposure to AMD's daily stock performance. While AMD's growth is driven by enterprise AI and a shift from GPU to CPU server markets, the ETF's leverage introduces volatility and r...
Bloom Energy reported a 165.5% year-over-year revenue increase and a 738% surge in EBIT for Q2 2026, driven by strong demand related to AI and data centers. The company also generated positive cash flow and raised its full-year 2026 revenue guidance ...
A Cumberland-linked wallet withdrew 14.6 million Polygon (POL) tokens worth $1.41 million from major exchanges, reducing supply on order books. Despite this, Polygon faces intense selling pressure from institutions and individuals, with increased tok...
Stellar (XLM) surged 8.72% to $0.1945, leading gains in a mixed cryptocurrency market. The rise is linked to increased interest in blockchain solutions for cross-border payments. Other notable movers include Zcash up 8.21%, Uniswap up 7.55%, and XRP ...
Stellar (XLM) surged 8.72% to $0.1945, leading the crypto market's gainers as interest grows in blockchain for financial services, especially cross-border payments. Meanwhile, Filecoin (FIL) fell 8.58% to $0.9011, reflecting ongoing volatility in the...
